Finding the right tests…
Emergency services available 24 x 7
Emergency services available 24 x 7
Finding the right tests…
Hormonal
CA 19-9 is a carbohydrate marker that pancreatic and other digestive-tract cells can release in larger amounts when something is wrong, cancer included. It's mainly used after a pancreatic cancer diagnosis — to see how treatment is working, whether the tumour is growing or shrinking, and to watch for recurrence after surgery — rather than to find cancer in someone with no symptoms. That matters because some people's bodies simply don't produce CA 19-9, even with a cancer that usually raises it, so their test can look normal despite active disease. Ordinary conditions like gallstones, bile duct disease, pancreatitis, or cirrhosis can also push it up without cancer present, so it's never used alone to diagnose or rule out cancer.
This test measures CA 19-9 protein in a blood sample, reported in units per millilitre, drawn as a standard venous sample with no special preparation. A meaningful share of people are unable to produce this antigen at all, so a normal-looking result doesn't rule anything out for them. Your doctor will usually track this over a series of tests rather than a single draw, since the direction of change after treatment matters more than any one number.
CA 19-9 is a carbohydrate-based marker released by cells lining the pancreas and bile ducts, and cancer in those areas can drive it noticeably higher. It's one of the most thoroughly studied blood markers for pancreatic cancer, but that doesn't mean it works as a stand-alone diagnostic tool.
A meaningful share of people simply don't produce CA 19-9, cancer or no cancer, according to MedlinePlus. For those individuals, this test can look reassuringly normal even with an active pancreatic cancer, which is one reason it's never relied on alone.
On the other side, everyday conditions like gallstones, bile duct disease or infection, pancreatitis, or liver cirrhosis can all push CA 19-9 up without any cancer involved, per MedlinePlus. Because of both problems, this test earns its keep mainly in people who already have a pancreatic cancer diagnosis — tracking treatment response and watching for recurrence — rather than in general screening.
- Some people simply don't produce this marker at all - Several non-cancer conditions can raise it - Mainly useful once pancreatic cancer is already diagnosed
No. MedlinePlus states that healthcare providers don't use CA 19-9 results alone to screen for or diagnose cancer, since it isn't accurate enough on its own for someone without symptoms.
Some people's bodies simply don't produce CA 19-9, even when they have a cancer that usually raises it, according to MedlinePlus, so a normal result doesn't fully rule out cancer in those individuals.
MedlinePlus lists gallstones, bile duct infections or disease, pancreatitis, liver cirrhosis, and cystic fibrosis as non-cancer conditions that can raise CA 19-9.
This page is general information about the test, not medical advice. Your own report's reference ranges apply — please discuss your results with your doctor.
Labs flag a result as high above a specific cutoff printed on your report, and MedlinePlus notes that an elevated level doesn't automatically mean cancer, since several non-cancer conditions can raise it too. Ranges vary by lab, so check the reference value on your own report.
MedlinePlus describes using it to track cancer progression during treatment, help gauge treatment effectiveness, and watch for recurrence, usually alongside imaging rather than as a stand-alone check.
No. It raises concern and typically prompts further testing, but plenty of non-cancer conditions can also raise it, so MedlinePlus is clear it isn't used to diagnose cancer by itself.
No specific fasting requirement is described for this test, but ask your doctor or the centre when you book, since practice can vary.